FierceBiotech11d
GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased competition'
GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
MarketWatch11d
GSK cuts vaccine sales target on reduced demand
U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year, citing lower-than-expected demand. The company said it’s now expecting a low single-digit fall in vaccine sales this ...
STAT11d
Sales of GSK’s RSV vaccine down dramatically from last year
It was clear that GSK’s vaccine division would see lower sales this quarter. But sales of the RSV vaccine, called Arexvy, and the company’s shingles vaccine Shingrix were both below analysts ...
GSK Pharma stock gains over 3% after profit, revenue boost in Q2 earnings
Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...
The Financial Times11d
GSK lowers vaccine sales forecast as weak demand for RSV jab Arexvy takes toll
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...
This is Money11d
GSK shares fall as vaccine demand disappoints
GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...
Benzinga.com11d
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...
Yahoo Finance11d
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand
GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...
Yahoo Finance4d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...